Arena (ARNA) Shares Sink as Piper Jaffray Downgrade Weighs
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Rating Summary:
10 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
10 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Shares of Arena Pharma (Nasdaq: ARNA) are now down more than 12 percent following an earlier downgrade from Piper Jaffray's Edward Tenthoff. The analyst now rates the stock a Neutral, down from Overweight previously.
The stock has rallied more than 33 percent since the FDA issued briefing documents ahead of an Advisory Committee meeting on the cardiovascular risks of obesity drugs. Arena shares ran up by more than 30 percent over the previous four trading sessions (from March 20th to March 23rd) in anticipation of the meeting. The meeting will conclude Thursday.
Arena shares last traded at $2.85.
The stock has rallied more than 33 percent since the FDA issued briefing documents ahead of an Advisory Committee meeting on the cardiovascular risks of obesity drugs. Arena shares ran up by more than 30 percent over the previous four trading sessions (from March 20th to March 23rd) in anticipation of the meeting. The meeting will conclude Thursday.
Arena shares last traded at $2.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- RBC Capital Downgrades Downer EDI Ltd (DOW:AU) (DNERF) to Sector Perform
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
Create E-mail Alert Related Categories
Downgrades, Momentum MoversRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
